Sporadic or familial head neck paragangliomas enrolled in a single center: Clinical presentation and genotype/phenotype correlations

Head and Neck

Volumn 35, Issue 1, 2013, Pages 23-27

  Bacca, Alessandra ^a   Sellari Franceschini, Stefano ^a   Carrara, Davide ^a   Bernini, Matteo ^a   Zampa, Virna ^a   Taddei, Stefano ^a   Miccoli, Paolo ^a   Congregati, Caterina ^a   Simi, Paolo ^a   Ferrari, Mauro ^a   Bernini, Giampaolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

genotype; paragangliomas; phenotype; succinate dehydrogenase mutation

Indexed keywords

PROTEIN RET; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE AF2; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE C; SUCCINATE DEHYDROGENASE D; TUMOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FAMILY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HEAD AND NECK CANCER; HEAD NECK PARAGANGLIOMA; HUMAN; HUMAN TISSUE; MALE; PARAGANGLIOMA; PREVALENCE; PRIORITY JOURNAL; RELATIVE; TUMOR DIAGNOSIS; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PARAGANGLIOMA; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84871207072     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22910     Document Type: Article

References (27)

1. Davies L, Welch HG,. In:, DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and genetics of tumors of endocrine organs. Lyon: IARC Press; 2004.
2. Lack E, editor. Anatomy and physiology of peripheral arterial chemoreceptors. Philadelphia: Saunders; 2004.
3. Kupferman ME, Hanna EY,. Paragangliomas of the head and neck. Curr Oncol Rep 2008; 10: 156-161. (Pubitemid 351395476)
4. Neumann HP, Eng C,. The approach to the patient with paraganglioma. J Clin Endocrinol Metab 2009; 94: 2677-2683.
5. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F,. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 2007; 14: 935-956. (Pubitemid 351252428)
6. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K,. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 2009; 16: 391-400.
7. Klein RD, Lloyd RV, Young WF,. Hereditary paraganglioma-pheochromocytoma syndromes. GeneReviews [Internet]. In:, Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Seattle: University of Washington, Seattle; 2009.
8. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2010; 31: 41-51.
9. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009; 94: 2817-2827.
10. Burnichon N, Brière JJ, Libé R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19: 3011-3020.
11. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91: 827-836. (Pubitemid 43357746)
12. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292: 943-951. (Pubitemid 39097204)
13. [No authors listed] Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988; 45: 575-578.
14. Bausch B, Borozdin W, Mautner VF, et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007; 92: 2784-2792. (Pubitemid 47037390)
15. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54. (Pubitemid 32614017)
16. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23: 8812-8818. (Pubitemid 46211527)
17. Dannenberg H, Dinjens WN, Abbou M, et al. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clin Cancer Res 2002; 8: 2061-2066. (Pubitemid 34753574)
18. Young WF Jr,. Paragangliomas: clinical overview. Ann N Y Acad Sci 2006; 1073: 21-29. (Pubitemid 44911994)
19. Fakhry N, Niccoli-Sire P, Barlier-Seti A, Giorgi R, Giovanni A, Zanaret M,. Cervical paragangliomas: is SDH genetic analysis systematically required? Eur Arch Otorhinolaryngol 2008; 265: 557-563.
20. Baysal BE,. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 2003; 14: 453-459. (Pubitemid 37517346)
21. Baysal BE,. Genomic imprinting and environment in hereditary paraganglioma. Am J Med Genet C Semin Med Genet 2004; 129C: 85-90. (Pubitemid 38989135)
22. Taschner PE, Jansen JC, Baysal BE, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer 2001; 31: 274-281. (Pubitemid 32521758)
23. Baysal BE, Willett-Brozick JE, Filho PA, Lawrence EC, Myers EN, Ferrell RE,. An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. J Med Genet 2004; 41: 703-709. (Pubitemid 39208612)
24. Boedeker CC, Erlic Z, Richard S, et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2009; 94: 1938-1944.
25. Gaal J, van Nederveen FH, Erlic Z, et al. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2009; 94: 4367-4371.
26. Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 2010; 11: 366-372.
27. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP,. In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 2008; 49: 1232-1237.